Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 260

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 260
---
 risk premium equal to 30% of the loan amount. Furthermore,
upon the occurrence of an IPO for a toral offering of not less than $6,000, the Bridge Loan Lenders, shall be granted warrants to purchase
such number of ordinary shares equal to two times the loan amount based on a price per share equal to 75% of the lowest price per share
of the Company’s ordinary shares, during the first five trading days from the consummation of an IPO. As of January 24, 2025, the
Company raised $250 under such Bridge Loans.

<div align='center'>F-15

REGENTIS BIOMATERIALS LTD.

FINANCIAL STATEMENTS

AS OF AND FOR THE YEAR ENDED DECEMBER 31, 2023

U.S. DOLLARS IN THOUSANDS

INDEX</div>

| Report of Independent                                                           
 Registered Public Accounting Firm (PCAOB ID 1197)                               
 Balance Sheets As                                                               
 of and For The Year Ended December 31, 2023                                     
 Statements of Comprehensive                                                     
 Loss As of and For The Year Ended December 31, 2023                             | Page        
 F-17        
 F-18        
 F-19        |
|:--------------------------------------------------------------------------------|:------------|
| Statements of Temporary                                                         
 Equity and Shareholders’ Deficit As of and For The Year Ended December 31, 2023 | F-20        |
| Statements of Cash                                                              
 Flows As of and For The Year Ended December 31, 2023                            | F-21        |
| Notes to Financial Statements                                                   | F-22 - F-45 |

<div align='center'>- - - - - - - - - - - - - - -

F-16</div>

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Shareholders and Board of Directors of Regentis Biomaterials Ltd.

Opinion on the Financial Statements

We have audited the accompanying balance sheets
of Regentis Biomaterials Ltd. (the “Company”) as of December 31, 2023 and 2022 and the related statements of comprehensive
loss, changes in temporary equity and shareholders’ deficit and cash flows for the each of the two years in the period ended December
31, 2023 and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements
present fairly, in all material respects, the financial position of the